Skip to main content

Table 3 Treatment-related adverse events occurring in 10% or more of patients

From: A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Adverse event

No. of patients (N = 41)

All grades

Grade ≥ 3

Hypertension

27 (66%)

16 (39%)

Fatigue

22 (54%)

4 (10%)

Diarrhea

22 (54%)

1 (2%)

Nausea

20 (49%)

0 (0%)

Constipation

10 (24%)

0 (0%)

Headaches

10 (24%)

0 (0%)

Vomiting

9 (22%)

1 (2%)

Mucositis

6 (15%)

0 (0%)

Proteinuria

6 (15%)

3 (7%)

Dysgeusia

5 (12%)

0 (0%)

GERD

5 (12%)

0 (0%)

Anorexia

4 (10%)

0 (0%)

  1. GERD Gastroesophageal reflux disease